BromhexIne And Spironolactone For CoronаVirUs Infection Requiring HospiTalization
BromhexIne And Spironolactone For CoronаVirUs Infection Requiring HospiTalization
Patients with mild and severe COVID 19 will be randomized 1:1 into two groups: experimental,
 which will get bromhexine and spironolactone, and control. Patients will get investigated
 therapy for ten days. Change in clinical assessment score COVID 19 (CAS COVID 19) between
 baseline and 12th day will be evaluated as a primary endpoint. Forty-five-day risk of death
 or mechanical ventilation will also be assessed.
Inclusion Criteria:

 signed inform consent COVID 19 with the mild and severe course. The diagnosis could be made
 with positive polymerase chain reaction (PCR) (International Statistical Classification
 (ICD-10) code - U07.1) and/or virus pneumonia in computer tomography (ICD 10 code - U07.2)
 5. Lung exposure on CT more than 25% 6. Sp02 without supportive oxygen ≤ 93% 7. C-reactive
 protein > 60 mg/l or elevation of C reactive protein 3 times in 8-14 days after first
 symptoms

 Exclusion Criteria:

 -  pregnancy and breastfeeding

 -  hypersensitivity to Spironolactone

 -  hypersensitivity to Bromhexine

 -  Known liver failure

 -  Glomerular filtration rate <20 ml/ min

 -  physician judgment that the patient will need mechanical ventilation in 24 hours

 -  other indications for Spironolactone

 -  Active cancer